Anticancer agent 231
Anticancer agent 231 (Compound P5) is a tyrosine protein kinase inhibitor with a IC50 value of 3.95 μM. Anticancer agent 231 inhibits the cell viability, cell proliferation, cell migration and cancer dryness of triple negative breast cancer (TNBC) cells by targeting EGFR-ERK 1/2 signaling pathway, and is expected to play an important role in the field of TNBC disease therapy[1].
Product Specifications
CAS Number
[128519-30-2]
UNSPSC
12352005
Target
ERK
Type
Reference compound
Related Pathways
MAPK/ERK Pathway; Stem Cell/Wnt
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/anticancer-agent-231.html
Smiles
ClC1=CC=C(C2=NN(C3=CC=CC=C3)C(C4=CC=C(N(C)C)C=C4)C2)C=C1
Molecular Formula
C23H22ClN3
Molecular Weight
375.89
References & Citations
[1]Satriyo PB, et al. N-phenyl pyrazoline derivative inhibits cell aggressiveness and enhances paclitaxel sensitivity of triple negative breast cancer cells. Sci Rep. 2024 Jun 8;14 (1) :13200.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
ERK1; ERK2
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
AP9C732-01 1 mg
Recombinant Goat Insulin-Like Growth Factor I (IGF1), N-His and C-Myc
Ask
View Details AP9C732-02 100 µg
Recombinant Goat Insulin-Like Growth Factor I (IGF1), N-His and C-Myc
Ask
View Details 
AP9C732-03 20 µg
Recombinant Goat Insulin-Like Growth Factor I (IGF1), N-His and C-Myc
Ask
View Details 